140 related articles for article (PubMed ID: 9755590)
1. Changes in enzyme activity and expression of DHFR of Toxoplasma gondii by antifolates.
Baek EJ; Nam HW
Korean J Parasitol; 1998 Sep; 36(3):191-8. PubMed ID: 9755590
[TBL] [Abstract][Full Text] [Related]
2. Lipophilic antifolates as agents against opportunistic infections. 1. Agents superior to trimetrexate and piritrexim against Toxoplasma gondii and Pneumocystis carinii in in vitro evaluations.
Piper JR; Johnson CA; Krauth CA; Carter RL; Hosmer CA; Queener SF; Borotz SE; Pfefferkorn ER
J Med Chem; 1996 Mar; 39(6):1271-80. PubMed ID: 8632434
[TBL] [Abstract][Full Text] [Related]
3. In vitro generation of novel pyrimethamine resistance mutations in the Toxoplasma gondii dihydrofolate reductase.
Reynolds MG; Oh J; Roos DS
Antimicrob Agents Chemother; 2001 Apr; 45(4):1271-7. PubMed ID: 11257045
[TBL] [Abstract][Full Text] [Related]
4. Heterologous expression and characterization of the bifunctional dihydrofolate reductase-thymidylate synthase enzyme of Toxoplasma gondii.
Trujillo M; Donald RG; Roos DS; Greene PJ; Santi DV
Biochemistry; 1996 May; 35(20):6366-74. PubMed ID: 8639582
[TBL] [Abstract][Full Text] [Related]
5. Nonclassical 2,4-diamino-5-aryl-6-ethylpyrimidine antifolates: activity as inhibitors of dihydrofolate reductase from Pneumocystis carinii and Toxoplasma gondii and as antitumor agents.
Robson C; Meek MA; Grunwaldt JD; Lambert PA; Queener SF; Schmidt D; Griffin RJ
J Med Chem; 1997 Sep; 40(19):3040-8. PubMed ID: 9301666
[TBL] [Abstract][Full Text] [Related]
6. Knocking down of the DHFR-TS gene in Toxoplasma gondii using siRNA and assessing the subsequences on toxoplasmosis in mice.
Azimi-Resketi M; Eskandarian A; Ganjalikhani-Hakemi M; Zohrabi T
Acta Trop; 2020 Jul; 207():105488. PubMed ID: 32277926
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and antiparasitic and antitumor activity of 2, 4-diamino-6-(arylmethyl)-5,6,7,8-tetrahydroquinazoline analogues of piritrexim.
Rosowsky A; Papoulis AT; Forsch RA; Queener SF
J Med Chem; 1999 Mar; 42(6):1007-17. PubMed ID: 10090784
[TBL] [Abstract][Full Text] [Related]
8. 2,4-Diamino-6,7-dihydro-5H-cyclopenta[d]pyrimidine analogues of trimethoprim as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase.
Rosowsky A; Papoulis AT; Queener SF
J Med Chem; 1998 Mar; 41(6):913-8. PubMed ID: 9526565
[TBL] [Abstract][Full Text] [Related]
9. Identification of highly potent and selective inhibitors of Toxoplasma gondii dihydrofolate reductase.
Chio LC; Queener SF
Antimicrob Agents Chemother; 1993 Sep; 37(9):1914-23. PubMed ID: 8239605
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of dihydrofolate reductases from Toxoplasma gondii, Pneumocystis carinii, and rat liver by rotationally restricted analogues of pyrimethamine and metoprine.
Rosowsky A; Queener SF; Cody V
Drug Des Discov; 1999 Jul; 16(1):25-40. PubMed ID: 10466054
[TBL] [Abstract][Full Text] [Related]
11. Characterization of a lipophilic antifolate resistance provoked by treatment of mammalian cells with the antiparasitic agent pyrimethamine.
Assaraf YG; Slotky JI
J Biol Chem; 1993 Feb; 268(6):4556-66. PubMed ID: 8440739
[TBL] [Abstract][Full Text] [Related]
12. Expression of variant dihydrofolate reductase with decreased binding affinity to antifolates in MOLT-3 human leukemia cell lines resistant to trimetrexate.
Miyachi H; Takemura Y; Kobayashi H; Ando Y
Cancer Lett; 1995 Jan; 88(1):93-9. PubMed ID: 7850779
[TBL] [Abstract][Full Text] [Related]
13. 2,4-Diamino-5-substituted-quinazolines as inhibitors of a human dihydrofolate reductase with a site-directed mutation at position 22 and of the dihydrofolate reductases from Pneumocystis carinii and Toxoplasma gondii.
Rosowsky A; Mota CE; Queener SF; Waltham M; Ercikan-Abali E; Bertino JR
J Med Chem; 1995 Mar; 38(5):745-52. PubMed ID: 7877140
[TBL] [Abstract][Full Text] [Related]
14. Dihydrofolate reductase binding and cellular uptake of nonpolyglutamatable antifolates: correlates of cytotoxicity toward methotrexate-sensitive and -resistant human head and neck squamous carcinoma cells.
Chen G; Wright JE; Rosowsky A
Mol Pharmacol; 1995 Oct; 48(4):758-65. PubMed ID: 7476904
[TBL] [Abstract][Full Text] [Related]
15. Kinetic and molecular properties of the dihydrofolate reductase from pyrimethamine-sensitive and pyrimethamine-resistant clones of the human malaria parasite Plasmodium falciparum.
Chen GX; Mueller C; Wendlinger M; Zolg JW
Mol Pharmacol; 1987 Apr; 31(4):430-7. PubMed ID: 3553892
[TBL] [Abstract][Full Text] [Related]
16. Loss of folylpoly-gamma-glutamate synthetase activity is a dominant mechanism of resistance to polyglutamylation-dependent novel antifolates in multiple human leukemia sublines.
Liani E; Rothem L; Bunni MA; Smith CA; Jansen G; Assaraf YG
Int J Cancer; 2003 Feb; 103(5):587-99. PubMed ID: 12494465
[TBL] [Abstract][Full Text] [Related]
17. 2,4-Diaminothieno[2,3-d]pyrimidine lipophilic antifolates as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase.
Rosowsky A; Papoulis AT; Queener SF
J Med Chem; 1997 Oct; 40(22):3694-9. PubMed ID: 9357537
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of dihydrofolate reductase and cell growth by antifolates in a methotrexate-resistant cell line.
Hamrell MR
Oncology; 1984; 41(5):343-8. PubMed ID: 6540852
[TBL] [Abstract][Full Text] [Related]
19. Cells exposed to antifolates show increased cellular levels of proteins fused to dihydrofolate reductase: a method to modulate gene expression.
Mayer-Kuckuk P; Banerjee D; Malhotra S; Doubrovin M; Iwamoto M; Akhurst T; Balatoni J; Bornmann W; Finn R; Larson S; Fong Y; Gelovani Tjuvajev J; Blasberg R; Bertino JR
Proc Natl Acad Sci U S A; 2002 Mar; 99(6):3400-5. PubMed ID: 11891321
[TBL] [Abstract][Full Text] [Related]
20. 2,4-diamino-5-deaza-6-substituted pyrido[2,3-d]pyrimidine antifolates as potent and selective nonclassical inhibitors of dihydrofolate reductases.
Gangjee A; Vasudevan A; Queener SF; Kisliuk RL
J Med Chem; 1996 Mar; 39(7):1438-46. PubMed ID: 8691474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
